DOCTOR'S VIEW ARCHIVE
Post-Traumatic Stress Disorder - Treatment
The US Food and Drug Administration (FDA) approved
sertraline (Zoloft), a drug commonly used to manage depression, as
the first medication specifically for the treatment of post-traumatic
stress disorder.
Post-traumatic stress
disorder is a pattern of behavior that
develops after a traumatic event. A traumatic event in this context
is defined as one that may bring serious injury or death to oneself
or to another person. Traumatic events capable of causing post-
traumatic stress disorder include kidnapping, natural disasters
(hurricanes, earthquakes, tornadoes, floods, etc), physical and
sexual abuse, combat, drug abuse, and near-death experiences.
Historically referred to as "soldier's heart" and "shell shock"
because the behavior characteristic of post-traumatic stress disorder
was seen in men after wartime combat, the symptoms and behaviors of
post-traumatic stress disorder have been shown to occur in children,
adolescents, and adults.
Constellation of changes in post-traumatic stress
disorder
Post-traumatic stress disorder is a constellation of changes in
personality and behavior that begin after a traumatic event and
persist for more than a month. Following the traumatic event,
individuals who develop post-traumatic stress disorder may feel like
the everyday world is no longer real and that they are in a dream-
like state. They may feel that their minds are detached from their
emotions as well as from their physical bodies, a condition referred
to as dissociation.
Persons with post-traumatic stress disorder may continuously
experience flashbacks. During these flashbacks they relive the
traumatic event and reexperience feelings of intense fear and of
inability to escape from the traumatic event. Every effort is taken
to avoid actions or thoughts associated with the traumatic event in
order to prevent these flashbacks.
Ultimately, behavior becomes erratic and hyperactive, as if the
individual were constantly defending himself. For example, the
person may develop anxiety, have disturbed sleep, and be easily
startled. Over the long run this behavior can lead to complete
dysfunction with a sense of hopelessness, a total lack of self-
esteem, and overwhelming fear of people. There also may be substance
abuse (use of alcohol or narcotics, for example) and difficulty
maintaining existing relationships.
Variable duration of the disorder
In about half of the individuals with post-traumatic stress
disorder, the condition resolves within six months while the other
half continue to suffer for years. Post-traumatic stress disorder is
considered to be acute if symptoms and behaviors last less than three
months, chronic if symptoms and behaviors persist for more than three
months, and delayed in onset if symptoms and behaviors begin at least
six months after the traumatic event.
About 4% of the general population or approximately 10 million
people develop post-traumatic stress disorder each year. It is twice
as common in women as in men. In one study it was found to occur in
15% of war veterans up to19 years after combat. Several factors
including psychological traits, genetics factors and life experiences
may contribute to the likelihood of developing post-traumatic stress
disorder.
For most patients with post-traumatic stress disorder, treatment
has consisted of counseling, psychotherapy, or drugs. A combination
of these approaches is sometimes employed. We will focus here on
the drugs used for post-traumatic stress disorder.
Drug treatment of post-traumatic stress disorder
The erratic, hyperactive behavior, anxiety, and sleep disturbance
associated with post-traumatic stress disorder were first thought due
to over-activity of the sympathetic nervous system, the part of the
nervous system that is active when there is fear. For this reason,
children were treated with propranolol (Inderol) which blocks the
sympathetic nervous system. However, propranolol proved to provide
little benefit.
New research has revealed how severe trauma can produce long-term
changes in the nerves in the brain. In particular, it is now
believed that the problem is caused by alterations in the chemical
substances that nerves in the brain use to communicate with each
other, substances referred to as neurotransmitters. These
alterations in neurotransmitters may be responsible for the symptoms
and behaviors.
Treatment of post-traumatic stress disorder has therefore shifted
to drugs that target these chemical substances. For example,
antidepressants including imipramine and phenelzine (Nardil) that
alter neurotransmitters such as serotonin, norepinephrine, dopamine,
and acetylcholine have been found do more to reduce flashbacks and
the feelings of helplessness more than placebo (a dummy pill).
Unfortunately, however, side effects interfered with the long-term
use of these drugs.